{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=3",
    "query": {
      "intervention": "placebo inhaler",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 298,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:59:33.346Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05628740",
      "title": "Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Chronic Cough"
      ],
      "interventions": [
        {
          "name": "3 mg NOC-100 (via nebulizer)",
          "type": "DRUG"
        },
        {
          "name": "1 mg NOC-110 (via DPI) [1x 1 mg capsule]",
          "type": "DRUG"
        },
        {
          "name": "3 mg NOC-110 (via DPI)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (via DPI)",
          "type": "DRUG"
        },
        {
          "name": "6 mg NOC-110 (via DPI)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (via DPI) [2x Placebo capsules]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nocion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-02-07",
      "completion_date": "2022-10-25",
      "has_results": false,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05628740"
    },
    {
      "nct_id": "NCT01525615",
      "title": "A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Respimat inhaler",
          "type": "DEVICE"
        },
        {
          "name": "tiotropium+olodaterol (low dose)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium + olodaterol (high dose)",
          "type": "DRUG"
        },
        {
          "name": "placebo to tiotropium+olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 404,
      "start_date": "2012-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 15,
      "location_summary": "Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Livonia",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525615"
    },
    {
      "nct_id": "NCT02487446",
      "title": "Efficacy and Safety Study of QVA149 in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "QVA149",
          "type": "DRUG"
        },
        {
          "name": "Umeclidinium/vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo (umeclidinium/vilanterol)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (QVA149)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 357,
      "start_date": "2015-07-28",
      "completion_date": "2016-09-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 58,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Multiple Locations",
          "state": "Alabama"
        },
        {
          "city": "Multiple Locations",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02487446"
    },
    {
      "nct_id": "NCT01634152",
      "title": "Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium low dose mcg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 401,
      "start_date": "2012-07",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 10,
      "location_summary": "Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01634152"
    },
    {
      "nct_id": "NCT06040268",
      "title": "Advair HFA in Healthy and HAPE Predisposed Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Altitude Edema"
      ],
      "interventions": [
        {
          "name": "Advair HFA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2023-12-12",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06040268"
    },
    {
      "nct_id": "NCT03137992",
      "title": "Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Test Product (tiotropium bromide inhalation powder)",
          "type": "DRUG"
        },
        {
          "name": "Reference Product (Spiriva®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lupin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 377,
      "start_date": "2017-11-21",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-04-05",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 34,
      "location_summary": "Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137992"
    },
    {
      "nct_id": "NCT02207829",
      "title": "A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Umeclidinium",
          "type": "DRUG"
        },
        {
          "name": "Umeclidinium matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1017,
      "start_date": "2014-09-01",
      "completion_date": "2015-06-15",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 1,
      "location_summary": "Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207829"
    },
    {
      "nct_id": "NCT00529529",
      "title": "Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Indacaterol 300 μg",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol 50 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 805,
      "start_date": "2007-09",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-08-29",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 56,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529529"
    },
    {
      "nct_id": "NCT01696058",
      "title": "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1137,
      "start_date": "2012-09",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-25",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 94,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696058"
    },
    {
      "nct_id": "NCT03394989",
      "title": "BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchial Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone propionate/salmeterol 100/50 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cipla Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1366,
      "start_date": "2018-10-17",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-08-13",
      "last_synced_at": "2026-11-15T12:59:33.346Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03394989"
    }
  ]
}